학술논문

Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers.
Document Type
Article
Source
Investigational New Drugs; Aug2019, Vol. 37 Issue 4, p711-721, 11p
Subject
ADENOSINES
ADENOSINE monophosphate
CELL physiology
CELL receptors
CELLULAR signal transduction
DRUG-food interactions
DOSE-effect relationship in pharmacology
IMMUNOSUPPRESSIVE agents
PATIENT safety
PHOSPHORYLATION
STATISTICAL sampling
RANDOMIZED controlled trials
TREATMENT effectiveness
CHEMICAL inhibitors
PHARMACODYNAMICS
Language
ISSN
01676997
Abstract
Copyright of Investigational New Drugs is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)